Publisher
Public Library of Science (PLoS)
Reference40 articles.
1. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study;DF McDermott;J Clin Oncol,2016
2. Release the Hounds! Activating the T-Cell Response to Cancer;M Sznol;The New England journal of medicine,2015
3. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab;DF McDermott;J Clin Oncol,2015
4. Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1;A Assal;Immunotherapy,2015
5. Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators;I Le Mercier;Frontiers in immunology,2015
Cited by
128 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献